NeuroNOS

What NeuroNOS does

NeuroNOS Ltd. is a pre-commercial biopharmaceutical company developing small-molecule therapeutics that target neuronal nitric oxide synthase (nNOS) to regulate nitric oxide (NO) levels in the brain. Founded in 2024 as a subsidiary of Beyond Air Inc. (NASDAQ: XAIR), the company focuses on neurological and neuro-oncology indications with high unmet need, including Autism Spectrum Disorder (ASD), Phelan-McDermid Syndrome (PMS), Glioblastoma (GBM), and Alzheimer's disease. The company is incorporated in Dublin, Ireland, with operations based in Boston, Massachusetts, and is led by CEO Amir Avniel and CSO Prof. Haitham Amal, whose laboratory at the Hebrew University of Jerusalem originated the underlying nitric oxide–autism research. As of January 2026, XTL Biopharmaceuticals Ltd. has entered a binding agreement to acquire 85% of NeuroNOS, with Beyond Air retaining a 19.99% stake post-transaction.

The company's core technology is the NO Modulation Platform, which produces small-molecule nNOS inhibitors designed to cross the blood-brain barrier. Lead candidate BA-102 targets core symptoms of ASD and has received FDA Orphan Drug Designation for PMS (April 2025); BA-101 targets GBM and received FDA Orphan Drug Designation in September 2025. The approach has been validated preclinically in over 700 animals across three ASD mouse models, supplemented by human stem cell–derived neurons and patient blood samples. Five patent families protect the platform, and a Scientific Advisory Board comprising Nobel laureates Prof. Roger Kornberg and Prof. Dan Shechtman provides external scientific validation. First-in-human U.S. clinical trials for BA-102 in ASD are planned for 2026.

NeuroNOS is pre-revenue with no commercialized products. The intended business model is traditional pharmaceutical product sales following FDA approval, supplemented by orphan-drug market exclusivity (seven years post-approval) on designated indications. The current revenue model is effectively grant- and equity-funded R&D, with $2.0 million in seed equity raised in March 2025 from private investors supporting preclinical and formulation development (subcutaneous formulation in progress, oral formulation planned). Go-to-market upon commercialization will rely on specialty pharmacy and hospital formulary channels typical of orphan CNS drugs, with clinical trial site distribution during development. Pricing details will be set post-approval.

Name

NeuroNOS

Legal name

NeuroNOS Ltd.

Website

https://neuro-nos.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

1–10 employees

Short description

NeuroNOS Ltd. is a pre-commercial biopharmaceutical company developing small-molecule nNOS inhibitors to treat Autism Spectrum Disorder, Phelan-McDermid Syndrome, Glioblastoma, and Alzheimer's disease, with first-in-human U.S. trials planned for 2026.

Ownership category

akta.pro rank

Product category

Neurological Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industries

Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Neuro-oncology (HLAKAIAL), Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF)

Keywords

• Small molecule therapeutics
• Neurological disorder treatments
• Autism spectrum therapy
• Nitric oxide modulation
• Glioblastoma treatment

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: As a pre-commercial biotech company developing novel therapeutics, NeuroNOS plans to generate revenue through the sale of FDA-approved pharmaceutical products. Lead programs include treatments for Autism Spectrum Disorder (BA-102) and Glioblastoma (BA-101). Revenue streams will come from prescription drug sales following regulatory approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

NeuroNOS is a clinical-stage biopharmaceutical company developing small-molecule drugs that target neuronal nitric oxide synthase (nNOS) to regulate nitric oxide (NO) levels in the brain. Its lead asset BA-102 is being advanced for Autism Spectrum Disorder (ASD) and Phelan-McDermid Syndrome (PMS), while BA-101 targets Glioblastoma. The company's compounds are designed to cross the blood-brain barrier and address core symptoms or disease mechanisms rather than secondary effects.

Product overview

NeuroNOS is a biopharmaceutical company developing small-molecule drugs for neurological disorders and neuro-oncology. The company's core offering is a NO Modulation Platform that produces therapeutic candidates (BA-102 and BA-101) targeting nitric oxide pathways in the brain. BA-102 is the lead candidate for Autism Spectrum Disorder and Phelan-McDermid Syndrome, while BA-101 targets Glioblastoma. Both are small-molecule therapies designed for subcutaneous injection or oral administration that cross the blood-brain barrier to regulate nitric oxide levels.

Differentiator

Problem solved

Functional benefit

Products and services

• BA-102

Quantifiable outcome

• Reversal of ASD-like phenotypes in preclinical models
• +5 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Hebrew University of Jerusalem (HUJI)coreStrategic or Co-development PartnerTechnology licensing partnership for selective neuronal nitric oxide synthase (nNOS) inhibitors for ASD treatment. Research originated from Prof. Haitham Amal's work at HUJI's School of Pharmacy. The partnership provides IP access and ongoing research collaboration. HUJI produces a third of Israel's civilian research and ranks 12th worldwide in biotechnology patent filings.
• YissumcoreStrategic or Co-development PartnerTechnology transfer company of Hebrew University of Jerusalem. Founded 1964, serves as bridge between academic research and commercialization. Has registered over 11,500 patents globally, licensed over 1,140 technologies, and spun out more than 245 companies. Facilitates the HUJI-NeuroNOS partnership for NO modulation technology.
• Harvard Medical School / Boston Children's HospitalminorStrategic or Co-development PartnerProf. Haitham Amal serves as Visiting Professor at Boston Children's Hospital, Harvard Medical School. Ongoing scientific collaboration and access to research infrastructure.
• Broad Institute of MIT and HarvardminorStrategic or Co-development PartnerProf. Amal was an affiliate in the Stanley Center for Psychiatric Research at the Broad Institute during postdoctoral work. The institute represents a collaborative research network for neuroscience research.
• MIT (Massachusetts Institute of Technology)minorStrategic or Co-development PartnerProf. Amal conducted postdoctoral studies at MIT and was a Senior Postdoctoral Associate in the Biological Engineering Department. Research collaboration and academic network.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Axial Therapeutics: Clinical-stage biotech developing gut-brain axis therapies for neurological conditions including ASD and Fragile X syndrome. Directly comparable as a CNS-focused company pursuing novel mechanisms in underserved neurodevelopmental indications.
• Yamo Pharmaceuticals: Late-stage biotech developing L-tyrosine (YT-100) for core symptoms of ASD. Closely comparable in therapeutic area, target indication (core ASD symptoms), and pre-commercial stage with novel CNS mechanisms.
• Ovid Therapeutics: Clinical-stage biopharma developing treatments for rare neurological and neurodevelopmental disorders including Angelman syndrome and other CNS conditions. Comparable in rare/neurodevelopment focus and pre-commercial small-molecule pipeline.
• MapLight Therapeutics: Clinical-stage CNS company developing therapies for schizophrenia, ASD, and other brain disorders. Comparable in CNS pipeline targeting underserved neuropsychiatric indications and platform-based approach.
• Kazia Therapeutics: Clinical-stage oncology company developing therapies for glioblastoma and other brain cancers. Directly comparable as a small-cap GBM-focused biotech with regulatory designations and a CNS oncology pipeline.
• CNS Pharmaceuticals: Clinical-stage biotech developing therapies for primary and metastatic brain cancers, with lead GBM program. Comparable in neuro-oncology focus, indication overlap (GBM), and pre-commercial small-cap stage.
• Denovo Biopharma: Clinical-stage biopharma developing precision medicines for CNS and oncology indications including glioblastoma. Comparable as a small-cap with brain-tumor pipeline programs and a biomarker-driven approach.

Broad incumbents

• Sage Therapeutics: Established CNS biopharma with FDA-approved Zurzuvae for postpartum depression and a broader neurology pipeline. Comparable as a CNS-focused innovator in neuropsychiatry, though at a more advanced commercial stage.
• Jazz Pharmaceuticals: Global biopharma with a significant CNS/neurology franchise (including GW Pharma's Epidiolex for rare epilepsies). Comparable as a broader player in rare neurological disorders with a CNS small-molecule portfolio.
• Roche: Large pharmaceutical company with one of the broadest ASD clinical pipelines in big pharma, including multiple programs targeting core symptoms. Relevant as a large incumbent competitor in the same therapeutic space.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Neuro_NOS
• LinkedInlinkedin.com/company/neuro-nos-n

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeuroNOS